Sean Parker (Facebook) is now a substantial holder

[Farma Zutical]

Clinuvel just released an ASX announcement about who became a substantial holder after the placement in May.

Link: http://www.aspecthuntley.com.au/asxdata/20130917/pdf/01444332.pdf

It appears that a company - SNP VENTURES - partly or fully owned by Sean Parker, I haven't been able to verify, bought for $ 5 mio shares. Mr. Parker is a 32 year old entrepreneur mostly known for his involvement in Facebook and Napster. Here is a copy paste of his bio:

"Part tech genius, part bad-boy, Sean Parker has displayed uncanny foresight and comprehension of Internet business strategy. However, his fondness for hard partying and run-ins with the law have also left him as the odd-man out in business ventures. At the age of 16, Parker's Virginia home was raided by the FBI when he was caught hacking systems of Fortune 500 companies. In 1999, at the age of 19, he co-founded the file sharing (and wrong-side-of -copyright-law) music service, Napster. At a trendy Chinese restaurant in New York in 2004, Parker met Facebook co-founder Mark Zuckerberg and became a mentor and advisor to the rising entrepreneur. Much like Napster, Parker was able to foresee Facebook's success and societal contributions only months into its inception. Acting as the company's first President, Parker negotiated a deal with Facebook's first investors Peter Thiel and Accel Partners, giving Zuckerberg absolute control of the board of directors. Ousted from Facebook in 2005 for a drug-related arrest, Parker went on to become Managing Partner of Founders Fund, a San Francisco-based venture capital shop. Parker still acts as an informal advisor to Zuckerberg. - See more at: http://whoownsfacebook.com/#sthash.j1SriPD4.dpuf"

Michael Polansky co-founded Parker's newest initiative, Airtime, and used to be in Founders Fund:

http://www.foundersfund.com/_archive/michaelpolansky.php

[Uhohinc]

Most here probably saw Sean Parker potrayed by Justin Timberlake in the Arron Sorensen well researched docudrama (I think it was him) about Zuckerburg/Facebook "The Social Network"

Even if SNP is not Sean N. Parker, Silicone Valley and it's venture capital investment firms
Which are in and a part of the dynamics and unprecedented synergy of no comparison where the geographic concentration of every facet of creative minds focused in computer sciences (a engineering degree from Stanford or a 'hacker' self education ) can readily find investment money and employment and a population focused on the technology, the future, and the rewards.
It's a similar concentration like Hollywood is to movie financing, actors, writers, producers, directors, prop wherehouses etc But then the peripherals of specialized technical and particular to that industry that are Relavant.

Silicone valley is the most energetic networking and investment open secrets that is the first and
likely only Place to create and nurture computer science startups and buyouts/mergers...... I can not think of too many better names or places then Sean Parker, or Palo Alto based SNP to affiliate to Clinuvel.
Indeed I think the next major technological evolution (after a few others) in biological sciences and also in computer sciences, will be when they fully integrate.http://www.google.com/url?sa=t&source=web&cd=7&ved=0CBwQFjAG&url=http%3A%2F%2Fwww.sec.gov%2FArchives%2Fedgar%2Fdata%2F1528524%2F000152852411000002%2F0001528524-11-000002.txt&ei=9IE4UuKdOeLJiwKOr4HQDQ&usg=AFQjCNGE3z5FZwlNkNb3sRolb6J4Vze1Og&sig2=d_nBHvlLD-ZGRojX4C3m_A

[Farma Zutical]

I agree. And I am confident that Mr. Parker is one of the two investors who bought the app. 2,5 mio shares. Look at the bottom of the last page. S. Parker and M. Polansky.

[eytan...@gmail.com]

The dates don't match exactly but this is a part of the last placement, which was announced on 5 May ($6.3 million raised at $2.136 per share). If you take the amount he purchased ($5 million for 2,340,824 shares) you can tell the price he bought at was also $2.136 per share, almost to the cent. So it means about 80% of the last placement were his shares.

It's a good large holder to have. Wealthy enough that he'll never need to sell. He needs to urge Thiel and Zuckerberg to get on board.

[Uhohinc]

Sean Parker is in a very unique investment clique. He is an 'early' in investor in embryogenic cutting edge technology. His partners in various capital ventures are with a whose who of mostly extremely wealthy and ultra successful foresight and ultra successful payouts in science and technology that started as concepts to executions to commercialization to stock exponentials with names and company's that are common to all. His networking with other investment seedling capitalists includes Peter Thiel, Elliot Musgrove and many others less of billions.

Dr Wolgen certainly personally communicated Dr Wolgens knowledge and vision of this drug and answered and piqued the interest of Sean Parker and that had to be worth alot.

Perhaps Sean Parker sees a investment strategy and implication similar to Napster, Facebook, and others, but with more years of experience and savviness and avoid the mistakes in his beginning.

This is just the opposite of the kiss of death for Clinuvel and it's stock. And his name on title to 6 % of shares so far increasing his posture is a value in of itself and emblematic of big things he knows and sees I think beyond EPP and Vitiligo.

Anyone whom has second guessed themselves or played a what if game or woulda coulda shoulda can at least now ponder in consolation that big smart money is with their percieved dumb money !

http://m.youtube.com/watch?v=Ked4vecS-Hc&desktop_uri=%2Fwatch%3Fv%3DKed4vecS-Hc

Googling [Sean Parker Investments] has got many links to profile and learn where Sean Parker thinking might be.

[itunes...@gmail.com]

http://www.standup2cancer.org/press_release/view/su2c_and_cri_announce_new_immunology_translational_research_dream_team

“Because of my deep respect for the innovative approach to cancer research taken by Stand Up To Cancer, I wanted to support the creation of a team dedicated to this emerging area of research,” said tech entrepreneur and philanthropist Sean Parker. “I am delighted that SU2C and the Cancer Research Institute have combined their expertise to select a Dream Team with such great potential to move the field forward through cutting-edge technology and science.”

Let us not forget CUV 9900 is patented as a treatment for melanoma (doesn't mean it works, but it does mean someone thinks that it might). 
“There are significant amount of data demonstrating from the group in Cincinnati (Kadekaro) as well as other labs that MC1R agonists could be used in prevention of carcinogenesis. Regarding the use of MC1R agonists in already established tumors (expressing the functional MC1R receptor) more studies have to be done.


Who knows what was presented to Sean Parker, maybe it was this type of stuff. I wish Clinuvel would talk to the market about it.

[Farma Zutical]

It's also interesting to think about how the initial contact was established. Who called who ? Did Wolgen go to Palo Alto ? And as you say: What was presented to Mr. Parker ?

Even though he is super rich $ 5 mio is not an amount of money anyone would like to throw away. He must to some extend believe in this investment. Furthermore, he is known for investing in companies that eventually become house hold names and super brands. As Uho writes, Wolgen must have made a convincing case for the outlook of Scenesse. If it is CUV9900 or OTC / general protection against skin cancer, I don't know. But even though EPP is an important thing to treat because they suffer tremendously, I don't think Mr. Parker is in Clinuvel to treat 10.000 people only.

[essenecs]

Indeed, looking at other ventures of snp he never gives money in the 5 or more millions to anyone without giving input himself or taking some initiative that is a game changer in hindsight making the difference between success and failure, hero or zero.  So what could that be for clinuvel?  When will it be made known to the world what exactly his input is?
Will he come to the next AGM and talk?  What will he bring into biotech while normally he is only in webtechnology etc?  I did not see SNP take stock and then pulling out in no time for some reason.  Mostly he seems to stay in the game and collect the candy first.
Maybe the AGM will not be boring this year and include the US phase III data and the FDA feedback from the patient meeting.

Clinuvel, cuv9900 or wolgen are not the brands that will have a global reach.
Scenesse has all that potential, like facebook, spotify napster, viagra, aspirine etcetc .
Just that almost nobody knows it and it is not really for sale yet...

EMA people will not like this napster facebook venture capital known for blockbusters in the web industry while clinuvel is playing the part of the small humble biotech that wants to help the handful of epp patients.   I suppose and maybe that is the reason clinuvel waited so long to announce the May major shareholder only in September.  On the other hand EMA is putting itself out of the game more and more and shooting its own foot by endlessly delaying what is obvious and logical. (fast approval) US and Singapore will overtake very soon I expect in approval, growth and sales for epp but especially vitiligo in the East.

Clinuvel is like a steam or diesel train starting up very slowly with micro sales and sometimes even almost rolling backward but once the forward movement is there, it keeps going and is difficult to stop.
Decades of sales growth ahead, sustainable business model regardless of the ema mess-up. 

SNP is not known for its mistakes when investing but sure enough they also did not get the timing right this time with an expected approval in the first half of 2013...lets hope the approval will come at some  point early next year before they decide to step out again.
Wolgen has a terrible track record of missed timelines and SNP is not exactly known for his patience or forgiveness.



Op woensdag 18 september 2013 16:54:56 UTC+3 schreef Farma Zutical:

[Uhohinc]

My guess is that the "V C's" (venture capitalists)
Attend the JP Morgan Biotechnology convention each year in about January. Clinuvel has presented at many in past years. And that is where Sean Parker, or affiliates of Founders Fund or others related got the attention from Clinuvel. They do invest in biotech, as well as Elliot Musk space venture and I guess Tesla.

Interesting in that when Sean Parker was arrested the second time he had a bronchiodialtion prescription. I presume he has
asthma. And there are substantiating inferences from abstracts that Melanocyte stimulating hormone and further that mcr1 stimulation in particular will attenuate the longterm and acute immune response that is the resulting affect from a substance or particulate from outside the
body causing out of sync or disproportional
response-asthma attack. I think Any or at least the first msh approved will be capable to theraputicly attenuate asthma. Indeed, the university of Arizona Tuscon and other msh analogs were indicating successful treatment study's in asthma.

The mcr1 receptors on a Melanocyte, and the melaningenisis favoring emulaine over phenoemulaine that so far is the story
Of Scenesse.

There are over a trillion cells making a human. And there are about 240 types of cells. And I think so far as known, about 25 or so of the cell types have an melanocortin receptor 1.

Of course I do not want to make someone think a mast cell or a macrophage will RNA melanin!!

But the mcr 1 is not the cause of melaningenisis in a Melanocyte, it's just part of the pathway. The Dana Farber institute has proven that melaningenisis and tyrosine formations can be accomplished with Forshkolin from plants mostly from India. As well as some now rare infections.

It appears (conclusive to me) afamelanotide will reach mcr1 in every one of the innate immune cells and the adaptive immune cells.

I presume the pathways to several genes but most notable the p53 protien production in the Melanocyte will be unregulated (by downregulating the suppression genes) but also in the innate and adaptive immune cells.

The p53 cancer and anti-tumor and cell suicide, DNA repair, and scenscenn are getting more substantiated and natural msh causes the tan as a peripheral of P53 indirectly.

But the affects of Scenesse on these innate/adaptive cells, and in particular the adaptive immune cell response which goes into overdrive with a infection, or vaccine to attack and protect the human (and importantly the subsequent shutdown of the immune response and then tissue repair replace) are still a mystery mostly, with intriguing possabilitys that are inferred to and Antecdotally looking very good.

Just what other signals from other hormones, or cell signalling tells the msh to stop the immune response ??? The immune cells must be told to die off, and stop the overproduction...... But if to soon then that could even kill the host human.
And the premise of many autoimmune responses out of order ( it is most likely vitiligo is the treg cells killing melanocytes but still not understood to declare cause) is the cause of half of all human ailments.

The stem cells are to me still the big mystery to me with Melanocyte stimulating hormone and Scenesse. There is not enough known about them yet to infer what might be happening.

Do the different types of stem cells abide by the Hayflick principle, do they or when if they do, mitosis, or is it after committing to a cell type.
Are humans borne with a reservoir of finite stemcells lying dormant. What signals stem cell migration. What determines or directs the stem cell to become a certain cell. What causes increase or decrease of bone marrow stem cells.
What causes some cells to lifecycle a few days, some a few weeks (skin) some a few months(blood) and some for life and some to never die and divide endlessly (cancer)

I am watching and interested for what msh and Scenesse may affect in stem cells, if at all.

[Uhohinc]

Time Warner Cable has/had "The Social Network" this week.
In the movie and in reality, Sean Parker was shrewd, opportunistic, and the original investor partner in Facebook claimed he was tricked into thinking the lawyers represented him, signed over his %35 stockholdings to Sean Parker and his VC diluting only him. Mark Zuckerberg appeared to work with Sean Parker.

Granted, Sean Parker contributed tremendous in this early stage and transformation and move to Silicone valley. I think it would not be where and what it is today without Sean Parker.
Along with the two twin brothers whom settled original dispute after hiring Zuckerberg for $65 million, the original screwed out investor walked with undisclosed probably a billion. Sean Parker made several billion, as well as Zuckerberg.

But if anyone remembers "My Space " and it's rise and fall, Facebook has to look over it's shoulders constantly.

And Dr Wolgen and "original" Clinuvel stockholders must be vigilant.

Right now it's good to have Sean Parker......on our side. But he is opportunistic and is out to make himself alot of money. And he is very smart and has good lawyers, and he may want more control than stock.

The recording industry win against Sean Parker in court. But because if him they are all out of business.

[Uhohinc]

Sean Parker has an interest in Immunology, according to this article that has quotes and interviews. I give it much more credible accurate portrayal (which is impossible) then the movie script adapted for drama and exaggeration for emotion.
I based my previous judgements about him from what I believe is the more fictionalized and little based on the truth movie that misrepresented Sean Parker and Mark Zuckerburg.

If you read this with the context of Clinuvel in mind, I think Sean Parker is going to be extremely fortuitous for Clinuvel and it's stock.
And I think Sean Parker will be at apexes of other worldly breakthrus.
http://www.google.com/url?sa=t&source=web&cd=19&ved=0CIsBENUnMBI&url=http%3A%2F%2Fwww.vanityfair.com%2Fculture%2Ffeatures%2F2010%2F10%2Fsean-parker-201010&ei=7xk_UtPyC-OIiALg_IHQCw&usg=AFQjCNEG841LxvzPZIQFqvhzIPGyWEKHRQ&sig2=TdPVPFgMcXjlX5x9dQI54w

[Farma Zutical]

Logically, I think Sean Parker has insight to the Clinuvel strategy. And he must be confident that he can get a multiple return within a rather limited time frame - 1-2 years. Even less. That's the way investors like him operate. Therefore, I think EPP is irrelevant for him. Vitiligo is too far off. I think PW told Sean Parker about the OTR trial results coming up hopefully soon. Those results will largely determine if we have a drug with a world wide and very broad potential or a drug limited to patient populations with a more limited scope. Even though Vitiligo to us is a big thing I don't think Sean Parker has much interest even in that. Vitiligo is simply not big enough a problem to be in the league of Parker's other investments. OTR is pivotal and a sneak peak into what could be a breakthrough therapy for skin cancer. I think Parker was whispered in his ear that the results are great and that Clinuvel intents to file for Breakthrough Therapy with the FDA within a year or so.

[Uhohinc]

I agree that is the most plausible scenario.

The end game for Sean Parker certainly is a substantial increase in his original investment. That is or has been all our thinking as investors also, but there had to be an dialogue that we can interpret for our knowlege. SNP at that private arranged capital raising had to to be preceded by SNP somehow hearing of Clinuvel. Then initiation by SNP of personal contact by SNP to Dr Wolgen.

The dialogue between them resulted in SNP
interest and commitment to put in the money, at
a slightly above market price.

I agree with your logic. SNP is not an atypical investor. He in pattern and practice is proactive and goes in for big breakout technological successes, recognizing intrinsic value and forethoughted predicted outcomes for tremendous stock gains.

And I think your correct in stating SNP is about an 18 months to 30 months at most in expectation of the stock gain.

I think we can presume Dr Wolgen and SNP had a conversation that lucidates an scenario for Clinuvel that is tremendous.

I think you are correct in that EPP and Vitiligo are lesser likely scenario for SNP involvement.
To small a market and to far away.

SNP has to envision something big for this stock.
The only other scenario I can postulate is an Dr Wolgen showing SNP non-abstractive interest or tentative numbers in writing or discussioning with big Pharma as to prospective licensing, or royaltys, or merger, or geographic marketing agreements, or sellout by Clinuvel.

And I think Dr Wolgen is holding out for the right time and right price, but I think he will parse this drug out to others to progress in the so many therapeutic areas it has potentials.

I surmise Clinuvel has over a hundred letters from researchers requesting info and some free implants to investigate Sceness inter areas of research.

A couple posts back, I referenced the abstract by researchers whom put in thier Pre-introduction that Nutlin-3 was a mimmick of Melanocyte stimulating hormone.

These researchers took a complex scientifically enigmatic concept in the Foriegn language of hyper medical research jargon and handed us a
simple laypersons profound explanation with just small lines to connect between the dots.

Nutlin 3 is Scenesse !

And Nutlin 3 is realistically involved in biological processes and projected outcomes that reputable entities have expectations of ten billion
plus in sales per year.

A successful AK clinical trial result that validates
P53 and sequential pathways and genes would be a fundamental breakthru in cancer treatment.

It is expected to be there with Nutlin 3, as well as Kevetrin and several others with several protien affects the same as effects as Sceness
but Clinuvel is Far ahead and no side effects of much consequence....so far.

[Farma Zutical]

I sure hope that a buy out scenario isn't going to take place any time soon. And I don't hope that's why SNP is in.

I met a VP here in San Francisco the other day and I asked him what he thinks of a $ 5 mio investment in a small Australian biotech. His point was that it's not an amount of money that will keep SNP awake a night but on the other hand not money that you invest without a certain amount of dd. If things weren't that blurry and uncertain due to the EMA delay I would add to my position on the SNP news.

[Uhohinc]

Sean Parker "hobby" stated by this articles author to be research into immunology.

I think he is at the leading edge of knowledge to have invested with Clinuvel. The P 53 pathways and as yet unexplained mechanics of actions of how msh symphonically puts the myriad disarrayed immune response into homeostasis are forefront with afamelanotide.

http://www.google.com/url?q=http://online.wsj.com/article/SB10001424052702304106704579137811842119176.html&sa=U&ei=ZjxeUtnMJq6UigLks4HwBQ&ved=0CBAQqQIwAA&sig2=M07dH4Df6m4znkC2vHtaeg&usg=AFQjCNFyA9EVFyJrQJAjrlrappFeP7KWNw

[Uhohinc]

In this video on Youtube entitled "How Sean Parker Picks Investments" it gives insights into how he has applied his collective experiences and compounding knowledge into a perspective and outlook that he can relate pretty good in an unstructured or prepared presentation, in what appears to be a chance encounter in the parking lot of what I think is a Tuscon area resort or restaurant. As one of the comments at the bottom say, this is worth more than a business class by a economics professor.

This is relateable in the context as you watch it, as to how he may have applied these pontifications and personal dogma to his Clinuvel investment. Also worth noting, pay attention to the numerous times Sean Parker is trying to clear his throat of post nasal drip, or viscous phlegm. Some are very suttle, and most I suspect are not even consciencous to himself.  This could be from a spicy Mexican food with a reaction to caspacin in the chiles or salsa. Or an allergic reaction to any number of other foods or plant compounds that are maybe causing his mast cells to hyper produce histamines or swollen annoids.  Being that he does several types of different ways of attempts to clear the mucosa, I think it is a chronic rather than acute problem that he has, not directly related to the foods, but exasperated by them. Sean Parker is known to have asthma from internet sources, and this is another immunological disorder. It could be that he has a mild infection deep in the sinus cavity that his immune system has a difficulty in alleviating, but something is inputting to his immune cells to stick around to long.  A drug that may help in these types of bacterial infections is Tequin.  But ironically, a melanocyte stimulating hormone such that Scenesse is, would in my opinion end his chronic throat tickle by putting his immune response back into a reset homeostacis and make the signal chemicals caused by certain immune cells over proliferation and staying to long.http://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0CCsQtwIwAA&url=http%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3DKed4vecS-Hc&ei=r15qU4WECYyFogTf8YKoCA&usg=AFQjCNHw0MdL27AoyAw94c8oX5eB1OZRVA&sig2=aDkH0WfAsH1JIpuZB-NI3g&bvm=bv.66111022,d.cGU

[Uhohinc]

Tequin is no longer available in USA http://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&cad=rja&uact=8&ved=0CDcQFjAB&url=http%3A%2F%2Fen.wikipedia.org%2Fwiki%2FGatifloxacin&ei=ymlqU5nYN9KBogShioLADA&usg=AFQjCNGLbkQa-eEaijLLc-jTL81-qWDeZg&sig2=fojgLZIkzwlQkE8tTjlOww&bvm=bv.66111022,d.cGU I found it to be an incredible at getting at hard to treat infections. I guess ciprioflaxin may be a substitute, but I never thought it as effective.

[Senn]

Most important takeaway for me in this interview is that he states that for 99.9% of the companies he gets shown, the market size isn't large enough to even consider the investment - and that to me means Sean Parker is not investing in Clinuvel for the EPP opportunity. He see's a much larger market opportunity ... vitiligo possibly or the possibility that Scenesse will prove to be effective in a NUMBER of conditions with LARGE MARKETS.

Senn

[Uhohinc]

That I agree with. But also his cut to the chase, can it make money. I think he was referencing the two entrepenuers and internet applications in general. But he summarizes the entire package he and vee cee's are looking for in an investment overall. He also emphasizes the so called 'team' and mocks I think its over use, but emphasis on the company management. And with his read on making his quick gut feeling on the "parasites" and the "fakers" and categorizing the people, I think he must have developed some opinion of Clinuvel management he must have met. I presume he had to meet or at least talk with Dr Wolgen. PW must have passed. Still wonder how Sean Parker learned of Clinuvel and its drug, and how he had an dialogue to know that he could pick up those created shares for his investment entity. I think there is a unknown and prior involvement. Parker appears to me to have decades of business experience that is real world, but he is not old enough. Most of it is all about dealing with people..................the simple interpersonal and communicative skill we all start developmentally learning in pre-school. But Parker appears to have some missteps in reading the papparazi press take on his wedding and New York condo renovation.  And his departure from the Founders Fund is so far remarkable in that it is still kept quiet as to why.

 As a wise old lady said one time...............two people is a relationship.........three or more is politics.

[Uhohinc]

More by Sean Parker and Mr. Breyer of Founders Fund discussing tech, companys, investing, managements, the future.http://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=16&cad=rja&uact=8&ved=0CFAQFjAFOAo&url=http%3A%2F%2Fwww.cnet.com%2Fnews%2Fsean-parker-thinks-silicon-valley-is-in-trouble%2F&ei=WzZrU-GkGs3qoATVw4DICg&usg=AFQjCNGQybmOqZq4a9ySR4OWPh8Zqho0JA&sig2=gJigsmhnoZHH9jycVOK_MA The suargo cactus and palo verde trees in background could only be Arizona. The golf cart says resort hotel, and the mountains preclude it from being Phoenix, {Camelback is very distinct} I think they were at Tuscon at I think the Vantana.

[Uhohinc]

Michael Polansky the agent of service for SNP Ventures Group filed feb 13, 2013. Now they have opened another Limited Liability Company............javascript:__doPostBack('ctl00$content_placeholder_body$SearchResults1$GridView_SearchResults_LPLLC','DetailLPLLC$0')

[Uhohinc]

Entity Name:	SNP VENTURES SPECIAL OPPORTUNITIES I, LLC
Entity Number:	201411410452
Date Filed:	04/22/2014
Status:	ACTIVE
Jurisdiction:	DELAWARE
Entity Address:	314 LYTTON AVE STE 200
Entity City, State, Zip:	PALO ALTO CA 94301
Agent for Service of Process:	MICHAEL POLANSKY
Agent Address:	314 LYTTON AVE STE 200
Agent City, State, Zip:	PALO ALTO CA 94301

[Uhohinc]

Other entities located at the same address as SNP Ventures Group LLC

<?xml version="1.0"?>

<edgarSubmission><schemaVersion>X0704</schemaVersion><submissionType>D</submissionType><testOrLive>LIVE</testOrLive><primaryIssuer><cik>0001528524</cik><entityName>Oeland Investments II LLC</entityName><issuerAddress><street1>314 LYTTON AVENUE, SUITE 200</street1><city>PALO ALTO</city><stateOrCountry>CA</stateOrCountry><stateOrCountryDescription>CALIFORNIA</stateOrCountryDescription><zipCode>94301</zipCode></issuerAddress><issuerPhoneNumber>(650) 804-7101</issuerPhoneNumber><jurisdictionOfInc>DELAWARE</jurisdictionOfInc><issuerPreviousNameList><value>None</value></issuerPreviousNameList><edgarPreviousNameList><value>None</value></edgarPreviousNameList><entityType>Other</entityType><entityTypeOtherDesc>Series LLC; Investment Series Dropbox, Inc.</entityTypeOtherDesc><yearOfInc><withinFiveYears>true</withinFiveYears><value>2011</value></yearOfInc></primaryIssuer><relatedPersonsList><relatedPersonInfo><relatedPersonName><firstName>N/A</firstName><lastName>AI Management LLC</lastName></relatedPersonName><relatedPersonAddress><street1>314 LYTTON AVENUE, SUITE 200</street1><city>Palo Alto</city><stateOrCountry>CA</stateOrCountry><stateOrCountryDescription>CALIFORNIA</stateOrCountryDescription><zipCode>94301</zipCode></relatedPersonAddress><relatedPersonRelationshipList><relationship>Director</relationship></relatedPersonRelationshipList><relationshipClarification>Manager to Issuer</relationshipClarification></relatedPersonInfo><relatedPersonInfo><relatedPersonName><firstName>Tom</firstName><lastName>van Loben Sels</lastName></relatedPersonName><relatedPersonAddress><street1>314 LYTTON AVENUE, SUITE 200</street1><city>Palo Alto</city><stateOrCountry>CA</stateOrCountry><stateOrCountryDescription>CALIFORNIA</stateOrCountryDescription><zipCode>94301</zipCode></relatedPersonAddress><relatedPersonRelationshipList><relationship>Director</relationship></relatedPersonRelationshipList><relationshipClarification>Managing Director of AI Management LLC which serves as Manager to Issuer</relationshipClarification></relatedPersonInfo><relatedPersonInfo><relatedPersonName><firstName>Jamie</firstName><lastName>Bush</lastName></relatedPersonName><relatedPersonAddress><street1>314 LYTTON AVENUE, SUITE 200</street1><city>Palo Alto</city><stateOrCountry>CA</stateOrCountry><stateOrCountryDescription>CALIFORNIA</stateOrCountryDescription><zipCode>94301</zipCode></relatedPersonAddress><relatedPersonRelationshipList><relationship>Director</relationship></relatedPersonRelationshipList><relationshipClarification>Managing Director of AI Management LLC which serves as Manager to Issuer</relationshipClarification></relatedPersonInfo><relatedPersonInfo><relatedPersonName><firstName>Jeffrey</firstName><lastName>Miner</lastName></relatedPersonName><relatedPersonAddress><street1>314 LYTTON AVENUE, SUITE 200</street1><city>Palo Alto</city><stateOrCountry>CA</stateOrCountry><stateOrCountryDescription>CALIFORNIA</stateOrCountryDescription><zipCode>94301</zipCode></relatedPersonAddress><relatedPersonRelationshipList><relationship>Director</relationship></relatedPersonRelationshipList><relationshipClarification>Managing Director of AI Management LLC which serves as Manager to Issuer</relationshipClarification></relatedPersonInfo></relatedPersonsList><offeringData><industryGroup><industryGroupType>Pooled Investment Fund</industryGroupType><investmentFundInfo><investmentFundType>Venture Capital Fund</investmentFundType><is40Act>false</is40Act></investmentFundInfo></industryGroup><issuerSize><revenueRange>Decline to Disclose</revenueRange></issuerSize><federalExemptionsExclusions><item>06</item><item>3C</item><item>3C.1</item></federalExemptionsExclusions><typeOfFiling><newOrAmendment><isAmendment>false</isAmendment></newOrAmendment><dateOfFirstSale><value>2011-11-21</value></dateOfFirstSale></typeOfFiling><durationOfOffering><moreThanOneYear>false</moreThanOneYear></durationOfOffering><typesOfSecuritiesOffered><isPooledInvestmentFundType>true</isPooledInvestmentFundType></typesOfSecuritiesOffered><businessCombinationTransaction><isBusinessCombinationTransaction>false</isBusinessCombinationTransaction><clarificationOfResponse/></businessCombinationTransaction><minimumInvestmentAccepted>0</minimumInvestmentAccepted><salesCompensationList/><offeringSalesAmounts><totalOfferingAmount>6000000</totalOfferingAmount><totalAmountSold>6000000</totalAmountSold><totalRemaining>0</totalRemaining><clarificationOfResponse/></offeringSalesAmounts><investors><hasNonAccreditedInvestors>false</hasNonAccreditedInvestors><totalNumberAlreadyInvested>20</totalNumberAlreadyInvested></investors><salesCommissionsFindersFees><salesCommissions><dollarAmount>0</dollarAmount></salesCommissions><findersFees><dollarAmount>0</dollarAmount></findersFees><clarificationOfResponse/></salesCommissionsFindersFees><useOfProceeds><grossProceedsUsed><dollarAmount>0</dollarAmount></grossProceedsUsed><clarificationOfResponse/></useOfProceeds><signatureBlock><authorizedRepresentative>false</authorizedRepresentative><signature><issuerName>Oeland Investments II LLC</issuerName><signatureName>/s/ Tom van Loben Sels</signatureName><nameOfSigner>Tom van Loben Sels</nameOfSigner><signatureTitle>Managing Director</signatureTitle><signatureDate>2011-12-02</signatureDate></signature></signatureBlock></offeringData></edgarSubmission>

[Uhohinc]

http://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=10&cad=rja&uact=8&ved=0CHMQFjAJ&url=http%3A%2F%2Fwww.graypools.com%2Finstitution%2Fai-management-llc%2Fventure-capital%2Foeland-investments-ii-llc&ei=FSt3U9uYEZG9oQS80IGAAQ&usg=AFQjCNFbIy0KkIu_mQeaLvcglumnwWhkOQ&sig2=N_SgUJ57_TkG23clBIZ4Qg&bvm=bv.66917471,d.cGU

On Saturday, May 17, 2014 2:19:15 AM UTC-7, Uhohinc wrote:

Other entities located at the same address as SNP Ventures Group LLC

<?xml version="1.0"?>

<edgarSubmission><schemaVersion>X0704</schemaVersion><submissionType>D</submissionType><testOrLive>LIVE</testOrLive><primaryIssuer><cik>0001528524</cik><entityName>Oeland Investments II LLC</entityName><issuerAddress><street1>314 LYTTON AVENUE, SUITE 200</street1><city>PALO ALTO</city><stateOrCountry>CA</stateOrCountry><stateOrCountryDescription>CALIFORNIA</stateOrCountryDescription><zipCode>94301</zipCode></issuerAddress><issuerPhoneNumber>(650) 804-7101</issuerPhoneNumber><jurisdictionOfInc>DELAWARE</jurisdictionOfInc><issuerPreviousNameList><value>None</value></issuerPreviousNameList><edgarPreviousNameList><value>None</value></edgarPreviousNameList><entityType>Other</entityType><entityTypeOtherDesc>Series LLC; Investment Series Dropbox, Inc.</entityTypeOtherDesc><yearOfInc><withinFiveYears>true</withinFiveYears><value>2011</value></yearOfInc></primaryIssuer><relatedPersonsList><relatedPersonInfo><relatedPersonName><firstName>N/A</firstName><lastName>AI Management LLC</lastName></relatedPersonName><relatedPersonAddress><street1>314 LYTTON AVENUE, SUITE 200</street1><city>Palo Alto</city><stateOrCountry>CA</stateOrCountry><stateOrCountryDescription>CALIFORNIA</stateOrCountryDescription><zipCode>94301</zipCode></relatedPersonAddress><relatedPersonRelationshipList><relationship>Director</relationship></relatedPersonRelationshipList><relationshipClarification>Manager to Issuer</relationshipClarification></relatedPersonInfo><relatedPersonInfo><relatedPersonName><firstName>Tom</firstName><lastName>van Loben Sels</lastName></relatedPersonName><relatedPersonAddress><street1>314 LYTTON AVENUE, SUITE 200</street1><city>Palo Alto</city><stateOrCountry>CA</stateOrCountry><stateOrCountryDescription>CALIFORNIA</stateOrCountryDescription><zipCode>94301</zipCode></relatedPersonAddress><relatedPersonRelationshipList><relationship>Director</relationship></relatedPersonRelationshipList><relationshipClarification>Managing Director of AI Management LLC which serves as Manager to Issuer</relationshipClarification></relatedPersonInfo><relatedPersonInfo><relatedPersonName><firstName>Jamie</firstName><lastName>Bush</lastName></relatedPersonName><relatedPersonAddress><street1>314 LYTTON AVENUE, SUITE 200</street1><city>Palo Alto</city><stateOrCountry>CA</stateOrCountry><stateOrCountryDescription>CALIFORNIA</stateOrCountryDescription><zipCode>94301</zipCode></relatedPersonAddress><relatedPersonRelationshipList><relationship>Director</relationship></relatedPersonRelationshipList><relationshipClarification>Managing Director of AI Management LLC which serves as Manager to Issuer</relationshipClarification></relatedPersonInfo><relatedPersonInfo><relatedPersonName><firstName>Jeffrey</firstName><lastName>Miner</lastName></relatedPersonName><relatedPersonAddress><street1>314 LYTTON AVENUE, SUITE 200</street1><city>Palo Alto</city><stateOrCountry>CA</stateOrCountry><stateOrCountryDescription>CALIFORNIA</stateOrCountryDescription><zipCode>94301</zipCode></relatedPersonAddress><relatedPersonRelationshipList><relationship>Director</relationship></relatedPersonRelationshipList><relationshipClarification>Managing Director of AI Management LLC which serves as Manager to Issuer</relationshipClarification></relatedPersonInfo></relatedPersonsList><offeringData><industryGroup><industryGroupType>Pooled Investment Fund</industryGroupType><investmentFundInfo><investmentFundType>Venture Capital Fund</investmentFundType><is40Act>false</is40Act></investmentFundInfo></industryGroup><issuerSize><revenueRange>Decline to Disclose</revenueRange></issuerSize><federalExemptionsExclusions><item>06</item><item>3C</item><item>3C.1</item></federalExemptionsExclusions><typeOfFiling><newOrAmendment><isAmendment>false</isAmendment></newOrAmendment><dateOfFirstSale><value>2011-11-21</value></dateOfFirstSale></typeOfFiling><durationOfOffering><moreThanOneYear>false</moreThanOneYear></durationOfOffering><typesOfSecuritiesOffered><isPooledInvestmentFundType>true</isPooledInvestmentFundType></typesOfSecuritiesOffered><businessCombinationTransaction><isBusinessCombinationTransaction>false</isBusinessCombinationTransaction><clarificationOfResponse/></businessCombinationTransaction><a style="color: blue; margin-left: -2em;" xmlns="http://www.w3.org/19

...

[Uhohinc]

http://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0CCsQFjAA&url=http%3A%2F%2Fwww.foundersfund.com%2F_archive%2Fmichaelpolansky.php&ei=yEiFU47wJtWuyATqkoHgBg&usg=AFQjCNEDrkZ4E5_SMAYAjer_ItfwElbCBw&sig2=MvR3U_ooxCpl5H_UAlaoTQ&bvm=bv.67720277,d.aWw

<?xml version="1.0"?>

<edgarSubmission><schemaVersion>X0704</schemaVersion><submissionType>D</submissionType><testOrLive>LIVE</testOrLive><primaryIssuer><cik>0001528524</cik><entityName>Oeland Investments II LLC</entityName><issuerAddress><street1>314 LYTTON AVENUE, SUITE 200</street1><city>PALO ALTO</city><stateOrCountry>CA</stateOrCountry><stateOrCountryDescription>CALIFORNIA</stateOrCountryDescription><zipCode>94301</zipCode></issuerAddress><issuerPhoneNumber>(650) 804-7101</issuerPhoneNumber><jurisdictionOfInc>DELAWARE</jurisdictionOfInc><issuerPreviousNameList><value>None</value></issuerPreviousNameList><edgarPreviousNameList><value>None</value></edgarPreviousNameList><entityType>Other</entityType><entityTypeOtherDesc>Series LLC; Investment Series Dropbox, Inc.</entityTypeOtherDesc><yearOfInc><withinFiveYears>true</withinFiveYears><value>2011</value></yearOfInc></primaryIssuer><relatedPersonsList><relatedPersonInfo><relatedPersonName><firstName>N/A</firstName><lastName>AI Management LLC</lastName></relatedPersonName><relatedPersonAddress><street1>314 LYTTON AVENUE, SUITE 200</street1><city>Palo Alto</city><stateOrCountry>CA</stateOrCountry><stateOrCountryDescription>CALIFORNIA</stateOrCountryDescription><zipCode>94301</zipCode></relatedPersonAddress><relatedPersonRelationshipList><relationship>Director</relationship></relatedPersonRelationshipList><relationshipClarification>Manager to Issuer</relationshipClarification></relatedPersonInfo><relatedPersonInfo><relatedPersonName><firstName>Tom</firstName><lastName>van Loben Sels</lastName></relatedPersonName><relatedPersonAddress><street1>314 LYTTON AVENUE, SUITE 200</street1><city>Palo Alto</city><stateOrCountry>CA</stateOrCountry><stateOrCountryDescription>CALIFORNIA</stateOrCountryDescription><zipCode>94301</zipCode></relatedPersonAddress><relatedPersonRelationshipList><relationship>Director</relationship></relatedPersonRelationshipList><relationshipClarification>Managing Director of AI Management LLC which serves as Manager to Issuer</relationshipClarification></relatedPersonInfo><relatedPersonInfo><relatedPersonName><firstName>Jamie</firstName><lastName>Bush</lastName></relatedPersonName><relatedPersonAddress><street1>314 LYTTON AVENUE, SUITE 200</street1><city>Palo Alto</city><stateOrCountry>CA</stateOrCountry><stateOrCountryDescription>CALIFORNIA</stateOrCountryDescription><zipCode>94301</zipCode></relatedPersonAddress><relatedPersonRelationshipList><relationship>Director</relationship></relatedPersonRelationshipList><relationshipClarification>Managing Director of AI Management LLC which serves as Manager to Issuer</relationshipClarification></relatedPersonInfo><relatedPersonInfo><relatedPersonName><firstName>Jeffrey</firstName><lastName>Miner</lastName></relatedPersonName><relatedPersonAddress><street1>314 LYTTON AVENUE, SUITE 200</street1><city>Palo Alto</city><stateOrCountry>CA</stateOrCountry><stateOrCountryDescription>CALIFORNIA</stateOrCountryDescription><zipCode>94301</zipCode></relatedPersonAddress><relatedPersonRelationshipList><relationship>Director</relationship></relatedPersonRelationshipList><relationshipClarification>Managing Director of AI Management LLC which serves as Manager to Issuer</relationshipClarification></relatedPersonInfo></relatedPersonsList><offeringData><industryGroup><industryGroupType>Pooled Investment Fund</industryGroupType><investmentFundInfo><investmentFundType>Venture Capital Fund</investmentFundType><is40Act>false</is40Act></investmentFundInfo></industryGroup><issuerSize><revenueRange>Decline to Disclose</revenueRange></issuerSize><federalExemptionsExclusions><item>06</item><item>3C</item><item>3C.1</item></federalExemptionsExclusions><typeOfFiling><newOrAmendment><isAmendment>false</isAmendment></newOrAmendment><dateOfFirstSale><value>2011-11-21</value></dateOfFirstSale></typeOfFiling><durationOfOffering><moreThanOneYear>false</moreThanOneYear></durationOfOffering><a style="color: blue;" onmousedown="this.href='http://www.google.com/url?q\75http%3A%2F%2Fwww.sec.gov%2FArchives%2Fedgar%2Fdata%2F1528524%2F000152852411000002%2Fprimary_doc.xml%23\46sa\75D\46sntz\0751\46usg\75AFQjCNF_t6LdBooq9RY7xvwLSpPcI6qAAQ';return true;" onclick="this.href='http://www.google.com/url?q\75http%3A%2F%2Fwww.sec.gov%2FArchives%2Fedgar%2Fdata%2F1528524%2F000152852411000002%2Fprimary_doc.xml%23\46sa\75D\46sntz\0751\46usg\75AFQjCNF_t6LdBooq9RY7xvwLSpPcI6qAAQ';return true;" href="http://www.sec.gov/Archives/edgar/data/1528524/000152852411000002/

...

[Uhohinc]

And if this stock in Clinuvel does not work out, Sean Parker could probably use anyone interested as his full time window washer, I think I will try and be his pool man.http://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&cad=rja&uact=8&ved=0CDAQqQIwAQ&url=http%3A%2F%2Fwww.latimes.com%2Fbusiness%2Frealestate%2Fhot-property%2Fla-fi-hotprop-ellen-degeneres-20140707-story.html&ei=sDm7U8T3IcfioASmqoCoAQ&usg=AFQjCNEOI5aScPcHEv6-LTkod1lWPdHvDw&sig2=mhyQ453pkJehaSLeymgdEA&bvm=bv.70138588,d.cGU  The price he gave Ellen.................is about the entire market value of all Clinuvel stock.

On Tuesday, May 27, 2014 7:28:30 PM UTC-7, Uhohinc wrote:

http://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0CCsQFjAA&url=http%3A%2F%2Fwww.foundersfund.com%2F_archive%2Fmichaelpolansky.php&ei=yEiFU47wJtWuyATqkoHgBg&usg=AFQjCNEDrkZ4E5_SMAYAjer_ItfwElbCBw&sig2=MvR3U_ooxCpl5H_UAlaoTQ&bvm=bv.67720277,d.aWw

On Saturday, May 17, 2014 2:27:08 AM UTC-7, Uhohinc wrote:

http://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=10&cad=rja&uact=8&ved=0CHMQFjAJ&url=http%3A%2F%2Fwww.graypools.com%2Finstitution%2Fai-management-llc%2Fventure-capital%2Foeland-investments-ii-llc&ei=FSt3U9uYEZG9oQS80IGAAQ&usg=AFQjCNFbIy0KkIu_mQeaLvcglumnwWhkOQ&sig2=N_SgUJ57_TkG23clBIZ4Qg&bvm=bv.66917471,d.cGU

On Saturday, May 17, 2014 2:19:15 AM UTC-7, Uhohinc wrote:

Other entities located at the same address as SNP Ventures Group LLC

<?xml version="1.0"?>

<edgarSubmission><schemaVersion>X0704</schemaVersion><submissionType>D</submissionType><testOrLive>LIVE</testOrLive><primaryIssuer><cik>0001528524</cik><entityName>Oeland Investments II LLC</entityName><issuerAddress><street1>314 LYTTON AVENUE, SUITE 200</street1><city>PALO ALTO</city><stateOrCountry>CA</stateOrCountry><stateOrCountryDescription>CALIFORNIA</stateOrCountryDescription><zipCode>94301</zipCode></issuerAddress><issuerPhoneNumber>(650) 804-7101</issuerPhoneNumber><jurisdictionOfInc>DELAWARE</jurisdictionOfInc><issuerPreviousNameList><value>None</value></issuerPreviousNameList><edgarPreviousNameList><value>None</value></edgarPreviousNameList><entityType>Other</entityType><entityTypeOtherDesc>Series LLC; Investment Series Dropbox, Inc.</entityTypeOtherDesc><yearOfInc><withinFiveYears>true</withinFiveYears><value>2011</value></yearOfInc></primaryIssuer><relatedPersonsList><relatedPersonInfo><relatedPersonName><firstName>N/A</firstName><lastName>AI Management LLC</lastName></relatedPersonName><relatedPersonAddress><street1>314 LYTTON AVENUE, SUITE 200</street1><city>Palo Alto</city><stateOrCountry>CA</stateOrCountry><stateOrCountryDescription>CALIFORNIA</stateOrCountryDescription><zipCode>94301</zipCode></relatedPersonAddress><relatedPersonRelationshipList><relationship>Director</relationship></relatedPersonRelationshipList><relationshipClarification>Manager to Issuer</relationshipClarification></relatedPersonInfo><relatedPersonInfo><relatedPersonName><firstName>Tom</firstName><lastName>van Loben Sels</lastName></relatedPersonName><relatedPersonAddress><street1>314 LYTTON AVENUE, SUITE 200</street1><city>Palo Alto</city><stateOrCountry>CA</stateOrCountry><stateOrCountryDescription>CALIFORNIA</stateOrCountryDescription><zipCode>94301</zipCode></relatedPersonAddress><relatedPersonRelationshipList><relationship>Director</relationship></relatedPersonRelationshipList><relationshipClarification>Managing Director of AI Management LLC which serves as Manager to Issuer</relationshipClarification></relatedPersonInfo><relatedPersonInfo><relatedPersonName><firstName>Jamie</firstName><lastName>Bush</lastName></relatedPersonName><relatedPersonAddress><street1>314 LYTTON AVENUE, SUITE 200</street1><city>Palo Alto</city><stateOrCountry>CA</stateOrCountry><stateOrCountryDescription>CALIFORNIA</stateOrCountryDescription><zipCode>94301</zipCode></relatedPersonAddress><relatedPersonRelationshipList><relationship>Director</relationship></relatedPersonRelationshipList><relationshipClarification>Managing Director of AI Management LLC which serves as Manager to Issuer</relationshipClarification></relatedPersonInfo><relatedPersonInfo><relatedPersonName><firstName>Jeffrey</firstName><lastName>Miner</lastName></relatedPersonName><relatedPersonAddress><street1>314 LYTTON AVENUE, SUITE 200</street1><city>Palo Alto</city><stateOrCountry>CA</stateOrCountry><stateOrCountryDescription>CALIFORNIA</stateOrCountryDescription><zipCode>94301</zipCode></relatedPersonAddress><relatedPersonRelationshipList><relationship>Director</relationship></relatedPersonRelationshipList><relationshipClarification>Managing Director of AI Management LLC which serves as Manager to Issuer</relationshipClarification></relatedPersonInfo></relatedPersonsList><offeringData><industryGroup><industryGroupType>Pooled Investment Fund</industryGroupType><investmentFundInfo><investmentFundType>Venture Capital Fund</investmentFundType><is40Act>false</is40Act></investmentFundInfo></industryGroup><issuerSize><revenueRange>Decline to Disclose</revenueRange></issuerSize><federalExemptionsExclusions><item>06</item><item>3C</item><item>3C.1</item></federalExemptionsExclusions><typeOfFiling><newOrAmendment><isAmendment>false</isAmendment></newOrAmendment><dateOfFirstSale><value>2011-11-21<s

...

[Uhohinc]

And with the CUV stock now at about $3.66 I think Sean Parker has well over 100% return on his money invested in Clinuvel.  Not quite a Facebook, or Spotify where he made billions........................................yet!

[Uhohinc]

Sean Parker Gives $24M to Stanford for Allergy Research

(Page 1 of 1)

• Sean Parker, Silicon Valley entrepreneur (Napster, Facebook, and Spotify are among his ventures) and philanthropist has pledged $24 million to Stanford University School of Medicine to fund the development of a new research center focused on allergy research.

  The Sean N. Parker Center for Allergy Research will be led by Kari Nadeau, M.D., Ph.D., an immunology researcher at Lucile Packard Children’s Hospital Stanford and the School of Medicine. Dr. Nadeau’s accomplishments include developing the first combination, multifood-allergy therapy that has been shown to safely desensitize food-allergic patients to up to five different allergens at the same time.

  “We need to make catalytic changes in the field of allergy research by studying immune mechanisms in order to apply discoveries in real time to new safer and more durable therapies for adults and children,” said Mr. Parker, whose firsthand experience with life-threatening allergies led him to found the Center.

  The Center will include Stanford specialists in diverse fields including immunology, gastroenterology, otolaryngology, chemistry, bioengineering, pathology, pulmonology, and genetics. Through laboratory and computational research, clinical trials, community outreach, and other efforts, the team will work toward finding rationally based therapies to provide the safest and best treatments for allergies. Research at the center may have implications for a wide array of immune dysfunctions including asthma, eczema, food allergies, eosinophilic disorders, drug allergies, gastroenterological diseases, and more.

  Mr. Parker's $24 million gift will provide both expendable and endowed support for innovative clinical research and care, state-of-the-art equipment, and top-ranked research scientists. Of the $24 million total, $4 million will be used to establish a dollar-for-dollar challenge match for all other new gifts to the center.

  Last year, Mr. Parker donated $1 million to The Cancer Research Institute to help fund the development of immune system based cancer treatments.

 

• inShare
•             
  
  

[Uhohinc]

http://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=10&ved=0CEkQFjAJ&url=http%3A%2F%2Fwww.biotechdaily.com.au%2Fmedia%2Fbackissues%2F2013%2F09%2520Sep%2FBD%2520Biotech%2520Daily%2520Sep%252017.pdf&ei=gV_3VLLKMpG4ogSagIHQBw&usg=AFQjCNGAJpvlnWt4y56jvNP7is146lI0dg&sig2=0MSG8Mh1Erfw8nxdHDQ88w&bvm=bv.87519884,d.cGU old news but more detail. Michael Polanski worked for Founders Fund, and Sean Parker.  $5million at 2.14 per share.

Sean Parker has almost died from allergic reactions from nuts, reportedly.

[Uhohinc]

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. The reader should not assume that the information is accurate and complete.
		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D Notice of Exempt Offering of Securities	OMB APPROVAL OMB Number: 3235-0076 Expires: August 31, 2015 Estimated average burden hours per response: 4.00

---

1. Issuer's Identity

CIK (Filer ID Number)	Previous Names	X None	Entity Type
0001604907			Corporation    Limited Partnership X Limited Liability Company    General Partnership    Business Trust    Other (Specify)
Name of Issuer
Brigade Media, LLC
Jurisdiction of Incorporation/Organization
DELAWARE
Year of Incorporation/Organization
Over Five Years Ago X Within Last Five Years (Specify Year) 2014    Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer
Brigade Media, LLC
Street Address 1		Street Address 2
314 LYTTON AVE., SUITE 200
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
PALO ALTO	CALIFORNIA	94301	(510) 520-0008

3. Related Persons

Last Name	First Name	Middle Name
Parker	Sean
Street Address 1	Street Address 2
314 Lytton Ave., Suite 200
City	State/Province/Country	ZIP/PostalCode
Palo Alto	CALIFORNIA	94301

Relationship:	X	Executive Officer		Director		Promoter

Clarification of Response (if Necessary):

Sole member of issuer

---

Last Name	First Name	Middle Name
Henke	David
Street Address 1	Street Address 2
314 Lytton Ave., Suite 200
City	State/Province/Country	ZIP/PostalCode
Palo Alto	CALIFORNIA	94301

Relationship:		Executive Officer		Director	X	Promoter

Clarification of Response (if Necessary):

Interested person in venture and its affiliates (non-affiliate)

---

Last Name	First Name	Middle Name
Thrall	John
Street Address 1	Street Address 2
314 Lytton Ave., Suite 200
City	State/Province/Country	ZIP/PostalCode
Palo Alto	CALIFORNIA	94301

Relationship:		Executive Officer		Director	X	Promoter

Clarification of Response (if Necessary):

Interested person in venture and its affiliates (non-affiliate)

---

Last Name	First Name	Middle Name
Conner	Adam
Street Address 1	Street Address 2
314 Lytton Ave., Suite 200
City	State/Province/Country	ZIP/PostalCode
Palo Alto	CALIFORNIA	94301

Relationship:		Executive Officer		Director	X	Promoter

Clarification of Response (if Necessary):

Interested person in venture and its affiliates (non-affiliate)

---

4. Industry Group

Agriculture Banking & Financial Services    Commercial Banking    Insurance    Investing    Investment Banking    Pooled Investment Fund Is the issuer registered as an investment company under the Investment Company Act of 1940?    Yes    No    Other Banking & Financial Services    Business Services Energy    Coal Mining    Electric Utilities    Energy Conservation    Environmental Services    Oil & Gas    Other Energy

Health Care    Biotechnology    Health Insurance    Hospitals & Physicians    Pharmaceuticals    Other Health Care    Manufacturing Real Estate    Commercial    Construction    REITS & Finance    Residential    Other Real Estate

Retailing Restaurants Technology    Computers    Telecommunications X Other Technology Travel    Airlines & Airports    Lodging & Conventions    Tourism & Travel Services    Other Travel Other

5. Issuer Size

Revenue Range		OR	Aggregate Net Asset Value Range
	No Revenues			No Aggregate Net Asset Value
	$1 - $1,000,000			$1 - $5,000,000
	$1,000,001 - $5,000,000			$5,000,001 - $25,000,000
	$5,000,001 - $25,000,000			$25,000,001 - $50,000,000
	$25,000,001 - $100,000,000			$50,000,001 - $100,000,000
	Over $100,000,000			Over $100,000,000
X	Decline to Disclose			Decline to Disclose
	Not Applicable			Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))    Rule 504 (b)(1)(i)    Rule 504 (b)(1)(ii)    Rule 504 (b)(1)(iii)    Rule 505 X Rule 506(b)    Rule 506(c)    Securities Act Section 4(a)(5)

Investment Company Act Section 3(c)    Section 3(c)(1)    Section 3(c)(9)      Section 3(c)(2)    Section 3(c)(10)    Section 3(c)(3)    Section 3(c)(11)    Section 3(c)(4)    Section 3(c)(12)    Section 3(c)(5)    Section 3(c)(13)    Section 3(c)(6)    Section 3(c)(14)    Section 3(c)(7)

7. Type of Filing

X	New Notice			Date of First Sale	2014-03-28				First Sale Yet to Occur
	Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year?

Yes X No

9. Type(s) of Securities Offered (select all that apply)

X	Equity		Pooled Investment Fund Interests
	Debt		Tenant-in-Common Securities
	Option, Warrant or Other Right to Acquire Another Security		Mineral Property Securities
	Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security		Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?

Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor

$0

USD

12. Sales Compensation

Recipient	Recipient CRD Number X None
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number X None
Street Address 1	Street Address 2
City	State/Province/Country	ZIP/Postal Code
State(s) of Solicitation (select all that apply) Check “All States” or check individual States    All States	Foreign/non-US

13. Offering and Sales Amounts

Total Offering Amount	$9,300,000	USD	or    Indefinite
Total Amount Sold	$9,300,000	USD
Total Remaining to be Sold	$0	USD	or    Indefinite

Clarification of Response (if Necessary):

14. Investors

	Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
	Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:	1

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	$0	USD	Estimate
Finders' Fees	$0	USD	Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

$0

USD

Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.* Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed. Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Brigade Media, LLC	/s/ Sean Parker	Sean Parker	Manager	2014-04-14

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.

[Uhohinc]

http://www.trulia.com/homes/California/San_Francisco/sold/7104853-2-Mint-Plz-501-San-Francisco-CA-94103

SNP now has it's mail going to this $5000 per month apartment/condo in the heart of San Francisco.  What Sean Parker should do, is open a Post Office Box at the local post office, and go online and have his mail forwarded to his apartment/condo. Thereby keeping his privacy.   Having all his investment entities going to this one address makes it easy to locate where he lives, and what he is up to.

 http://www.yelp.com/biz/mint-plaza-san-francisco  It is called "Mint" because it is or is near the old California gold rush era United States Mint ...............maybe a little innuendo for the stock SNP holds.

[Farma Zutical]

Someone posted this link on another board I am following and it's a good read. Very relevant as to how I see my investment in Clinuvel.

I think Sean Parker might agree.


http://microcapclub.com/2014/08/the-conviction-to-hold/

[RPape]

Have an exit strategy and stick to it no matter what.  Of course, a review every quarter or so of the company's health and your financial needs makes sense, but falling victim to the noise cannot happen.

 

  This tree shake will make $5 a very attractive selling point for many.  I'm keeping it simple by selling 1000 shares every $5, starting at $5.  Limit orders will be placed, thoughts will be eliminated.  The itchy trigger finger is a huge fear, which I've posted many times.  Roy Raymond is an inspiration in this regards.

CONFIDENTIALITY NOTICE: This email message is intended only for the person to whom it is addressed and may contain confidential and/or privileged material. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message. If you are the intended recipient but do not wish to receive communications through this medium, please so advise the sender immediately.

[Uhohinc]

https://news.yahoo.com/katie-couric-talks-to-sean-parker-former-facebook-president-023048895.html

Sean is committing hundreds of millions to cure cancer, allergic responses

[Uhohinc]

One thing Parker stated that is of note.  If one can slowly introduce microscopic amounts of an allergen to a human with a reaction to the allergan, and apparently the immune system adapts or stops attacking or responding.  Then why could not the immune cells become accustomed after awhile to the transducers/sensors to a cancer cell, and then let it live.

[Uhohinc]

http://money.cnn.com/2015/06/26/technology/sean-parker-hacker-philanthropy/

SNP to dedicate $600 million to philanthropic world changing endeavors. His focus is on medical breakthroughs and tech.  He found about Clinuvel by the internet per Dr. Wolgen. His personal interest is allergic reactions and immunology. I do not think he would focus on Scenesse as a photo theraputic drug. As a photo therapeutic, Scenesse does not stand out to the thousand plus other drug companys he could have invested into. Could he have interest in a "tanning " drug.  All plausible.  Not even a couple hundred humans could scour the internet and know just a little about all the drugs and knowledge of the human bio and know when to focus and then invest. As in this link, Sean Parker is still in affiliation with the Founders Fund if not on a financial basis, on personal level with Peter Thiel.  Thiel's interests, per his book (I have not read but heard about) is the future and focus on biology of human longevity.

Then there is the incidental that is more than  co in that there are related silicone valley investors in Clinuvel that affiliate with history to Parker and Thiel past investments.  At one time, Dr. Wolgen stated that Sean Parker discovered Clinuvel from some kind of parameter connected to the drugs popularity in internet activity. 

[snx]

I believe he discovered clinuvel via the first vitiligo youtube movie that went viral in number of views.
He noticed the odd numbers on some facebook (owners of youtube) charts and investigated.

Secondly to invest he must be convinced that scenesse is potentially disruptive technology and he knows all about that from experience.
Thirdly the name scenesse has been chosen deliberately by management with an aim to implicitly market the impact of the drug on the natural scenescence of human cells.  I suppose they know more about that kind of effects but simply do not communicate as they stated.
Positive impact, anti inflammatory and possibly extending life expectancy.

Once scenesse get's "traction" and passes a critical mass of patients, possibly upon availability of the topical application, the roof will be gone.
Not if but when.  EPP will not do it, vitiligo will be just the start.
By that time some mega pharmas will have firmly "positioned" themselves in the melanotide space.
Hopefully they will leave some fun for us too.
That is something comforting about the FIL and Parker investments.  We know that non of these two will let others steal our hard earned income.
They have plenty of cash and armies of lawyers to at least match any other deep pocket sharks in these waters.
If FIL, Parker, Management keep there piece of the pie there is a better chance that all shareholders will benefit.



Op dinsdag 17 september 2013 12:56:57 UTC+2 schreef Farma Zutical:

Clinuvel just released an ASX announcement about who became a substantial holder after the placement in May.

Link: http://www.aspecthuntley.com.au/asxdata/20130917/pdf/01444332.pdf

It appears that a company - SNP VENTURES -  partly or fully  owned by Sean Parker, I haven't been able to verify, bought for $ 5 mio shares. Mr. Parker is a 32 year old entrepreneur mostly known for his involvement in Facebook and Napster. Here is a copy paste of his bio:

"Part tech genius, part bad-boy, Sean Parker has displayed uncanny foresight and comprehension of Internet business strategy. However, his fondness for hard partying and run-ins with the law have also left him as the odd-man out in business ventures. At the age of 16, Parker's Virginia home was raided by the FBI when he was caught hacking systems of Fortune 500 companies. In 1999, at the age of 19, he co-founded the file sharing (and wrong-side-of -copyright-law) music service, Napster. At a trendy Chinese restaurant in New York in 2004, Parker met Facebook co-founder Mark Zuckerberg and became a mentor and advisor to the rising entrepreneur. Much like Napster, Parker was able to foresee Facebook's success and societal contributions only months into its inception. Acting as the company's first President, Parker negotiated a deal with Facebook's first investors Peter Thiel and Accel Partners, giving Zuckerberg absolute control of the board of directors. Ousted from Facebook in 2005 for a drug-related arrest, Parker went on to become Managing Partner of Founders Fund, a San Francisco-based venture capital shop. Parker still acts as an informal advisor to Zuckerberg. - See more at: http://whoownsfacebook.com/#sthash.j1SriPD4.dpuf"

Michael Polansky co-founded Parker's newest initiative, Airtime, and used to be in Founders Fund:

http://www.foundersfund.com/_archive/michaelpolansky.php

[Uhohinc]

One thought, is that Michael Polansky whom is in charge of several of Sean Parker investments holding entities, including the one bought into Clinuvel. There is a new one http://www.corporationwiki.com/California/San-Francisco/michael-polansky/107703143.aspx

Polansky on his Facebook front page has "Wired" as one of his favorites. Wired online and the magazine have published about Clinuvel and followed it for years. Just a guess, filling in between two dots.

[Uhohinc]

http://www.streetinsider.com/SEC+Filings/Form+4+OOMA+INC+For%3A+Jul+22+Filed+by%3A+Parker+Sean+N./10743773.html

Form 4 OOMA INC For: Jul 22 Filed by: Parker Sean N.

ArticleStock Quotes (1)Comments (0)

July 22, 2015 7:53 PM EDT Send to a Friend

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Expires: December 31, 2014 Estimated average burden hours per response: 0.5
			Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person * Parker Sean N. (Last) (First) (Middle) C/O OOMA, INC. 1880 EMBARCADERO ROAD (Street) PALO ALTO CA 94303 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol OOMA INC [ OOMA ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 07/22/2015
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/22/2015		C		42,667	A	$ 0	56,032	D
Common Stock	07/22/2015		C		51,280	A	$ 0	51,280	I	By SNP Ventures, LP. (1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series Alpha Convertible Preferred Stock	(2)	07/22/2015		C			42,667	(2)	(2)	Common Stock	42,667	$ 0	0	D
Series Beta Convertible Preferred Stock	(3)	07/22/2015		C			23,581	(3)	(3)	Common Stock	51,280	$ 0	0	I	By SNP Ventures, LP. (1)

Explanation of Responses:

1. Mr. Parker is an affiliate of SNP Ventures Fund LP and a beneficial owner of the shares.

2. The Series Alpha Convertible Preferred Stock converted into the issuer's common stock on a one-for-one basis upon the closing of the issuer's initial public offering. The Series Alpha Convertible Stock had no expiration date.

3. Each share of Series Beta convertible preferred stock converted into that number of the issuer's common stock equal to the ratio of $21.2028 divided by $9.75 upon the closing of the issuer's initial public offering. The Series Beta Convertible Stock had no expiration date.

	/s/ Spencer D. Jackson, as attorney-in-fact for Sean N. Parker	07/22/2015
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

[Uhohinc]

http://scienceofsingularity.com/tag/sean-parker/

Billionares and Biotech including Parker, Theil,

[Farma Zutical]

Sean Parker donates $250 million to establish a new cancer research center. If the end game with Scenesse will be a general protectant against skin cancer and if
that is amongst the reasons why Pamer invested in Clinuvel the new center might be able to help.

http://www.nbcnews.com/health/cancer/sean-parker-donates-250-million-launch-cancer-immunotherapy-institute-n555196

[Uhohinc]

Along with Parker's interest in immunotherapy, with what is now known this is also directly relatable to cancer, he has also set up LLC's for funding political initiatives in California. These are where the sponsor (Unique in California state constitutional law from state's inception in 1848) can get signatures from registered voters outside supermarkets or general public any proposal or idea and submit to the secretary of state. This circumvents the governor, legislative bodies, and all formal political and ways a law is normally passed.

Parker has at the same location of where he has set up the LLC's for investing in Clinuvel with SNP Ventures and Ender  (the other with that Lord of the Rings name) set up funding for his personal political processes and funding some of the supermarket signature gatherers.  The individuals outside Costco and Walmart get fee for each signature for each ballot initiative.  Just one Parker is sponsoring that I know of but I am not certain of, is for clarification of ambiguities on the marijuana proposition that passed in about 1994 which law enforcement is finding loopholes and conditionals in the "law". They are fair loopholes, purposed to get the "medical" use to get more votes at the time.

No other state does allow the "people' to pass a law this way that I know of. A more real democracy then representative democracy everywhere else. And when this method of proposing a law, and the then ballot for a majority passes it can not be usurped by the governor or legislature. It becomes a supreme law over all others that the state, county, or city can not change or conflict.

My guess based on Parker's situations in past with FBI and his music sharing company that he was forced by the now gone record companies into bankruptcy, his other silicone valley endeavors, and his dangerous allergies, and his political commentaries, his money pledge here is a genuine philanthropical  BUT, I opinion he  has a future interest in state and national political aspirations. Astoundingly to me is the American national news channel I just watched is still putting Trump sniveling  on the top of the news cycle over and over, and above Parker's collaborations with Stanford, UCLA and I missed the others for cancer cure.

[Uhohinc]

https://www.washingtonpost.com/business/sean-parker-silicon-valleys-bad-boy-geniuswants-to-beat-cancer/2016/04/15/095fe914-00e3-11e6-9d36-33d198ea26c5_story.html?utm_term=.9682d31631b7

Perhaps Dr Wolgen is attending Sean Parker networking partys.
Insights here that can maybe infer how Sean Parker "found" and invested in Clinuvel. If I recall he bought in at $1.88 per share I think US dollars, though not sure now.

[Uhohinc]

Parker Foundation goal to disrupt cancer begins first collaboration with outside pharma and a biotech for a trial in pancreatic cancer. The cancer with the worst outcome with least interventional therapies.https://www.parkerici.org/2017/09/20/sean-parkers-cancer-fighting-institute-aims-1st-trial-at-tough-target/

[Uhohinc]

Update

[Uhohinc]

A stealth start-up called 3T Biosciences has raised more than $12 million in a massive seed round led by early Facebook investor Sean Parker and including Peter Thiel, according to a person familiar with the company's financing.

Little is known about 3T Biosciences, but this person said the company is led by cancer biology PhD student and investor, Asset Management Ventures' principal Luke Lee, as well as a group of academics from Christopher Garcia's biology lab at Stanford.

3T Biosciences is in the T-cell therapy space, the person said, meaning that it is among a growing group of new start-ups working to bolster the body's own immune system to fight cancer. That's a different approach than traditional medicines like chemotherapy, which kill off both cancerous and healthy cells.

Sean Parker speaking at the 2015 CGI Annual Meeting in New York.
Adam Jeffery | CNBC
Sean Parker speaking at the 2015 CGI Annual Meeting in New York.
These approaches have not proved successful for all cancer patients and are still early. Juno Therapeutics, a Seattle-based company in the space, needed to halt development for its drug therapy after three patient deaths.

Still, Silicon Valley's venture investors see an opportunity to make a return with Gilead Sciences' recently acquiring cancer immunotherapy company Kite Pharma for $11.9 billion. That follows Abbvie's $10.2 billion acquisition of Founders Fund-backed cancer drug start-up Stemcentrx in 2016.

These venture firms also see potential to combine traditional drug therapeutics with new technologies like machine learning in the hopes of accelerating the timeline and reducing the cost of bringing a new drug to market.

The round was led by Parker through his venture fund, the person said, with participation from Thiel Capital and several other firms.

[Uhohinc]

Update

[Uhohinc]

https://www.washingtonpost.com/news/the-switch/wp/2018/04/02/spotify-ipo/
Sean Parker reported to own 5% of Spotify. He invested in it long term ago even before Clinuvel.

[Uhohinc]

https://www.businessinsider.com/lady-gaga-boyfriend-tech-ceo-michael-polansky-life-career-2020-2 dating Lady Gaga, intro by Sean Parker

[Uhohinc]

Sean Parker holds 2,340,824 shares of Clinuvel he bought at was also $2.136 per share. He has about 11 times the money he invested almost 8 years ago.